Alcami Corp., a contract development and manufacturing organization within the pharmaceutical industry, on Monday announced the retirement of Patrick Walsh and the subsequent appointment of Bill Humphries as the next CEO.

Humphries will also join the Alcami Corp. Board of Directors, according to a news release.

"I am excited to join Alcami and work alongside a tremendous leadership team and dedicated employees that are well respected in the life sciences industry," Humphries stated in the release.

Prior to Wilmington-based Alcami, Humphries' executive leadership roles included CEO at Isosceles Pharmaceuticals; president and group company chairman of Ortho-Dermatologics; CEO of Merz North America; president of Stiefel, a GSK company; and vice president of US Skincare at Allergan Pharmaceuticals, according to the release.

He is an experienced leader in the life sciences industry, serving as chairman of the board at Clearside Biomedical, executive chairman of Strata Skin Sciences and a member of the board of directors at Aclaris Therapeutics, PhaseBio Pharmaceuticals, SKNV and Bryn Pharmaceuticals.

Humphries' academic credentials include a bachelor's degree from Bucknell University and an MBA from Pepperdine University, the release stated.

"On behalf of our 1,000 employees and the Board of Directors, we welcome Bill to Alcami as he leads the company through the next phase of growth and expansion," Walsh stated in the release.

Walsh is retiring after a 42-year career in the pharmaceutical industry, including serving as CEO in six organizations, as a board of directors member in 15 organizations and as an operating partner and advisor to health care private equity organizations around the globe.